I guess that's why he received those 45M performance shares at 2c for just $2M revenue target.....I still think Painchek limitation is it isn't a totally objective pain assessment, hence big question mark around the global uptake and also whether there will be overwhelm uptake in Australia which is familiar of APS.
PCK Price at posting:
11.5¢ Sentiment: None Disclosure: Not Held
